Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Theiler, A; Konya, V; Pasterk, L; Maric, J; Bärnthaler, T; Lanz, I; Platzer, W; Schuligoi, R; Heinemann, A.
The EP1/EP3 receptor agonist 17-pt-PGE2 acts as an EP4 receptor agonist on endothelial barrier function and in a model of LPS-induced pulmonary inflammation.
Vascul Pharmacol. 2016; 87(4):180-189
Doi: 10.1016/j.vph.2016.09.008
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Heinemann Akos
- Theiler Anna
- Co-Autor*innen der Med Uni Graz
- Bärnthaler Thomas
- Konya Viktoria
- Lanz Ilse
- Maric Jovana
- Pasterk Lisa
- Platzer Wolfgang
- Schuligoi Rufina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Endothelial dysfunction is a hallmark of inflammatory conditions. We recently demonstrated that prostaglandin (PG)E2 enhances the resistance of pulmonary endothelium in vitro and counteracts lipopolysaccharide (LPS)-induced pulmonary inflammation in vivo via EP4 receptors. The aim of this study was to investigate the role of the EP1/EP3 receptor agonist 17-phenyl-trinor-(pt)-PGE2 on acute lung inflammation in a mouse model. In LPS-induced pulmonary inflammation in mice, 17-pt-PGE2 reduced neutrophil infiltration and inhibited vascular leakage. These effects were unaltered by an EP1 antagonist, but reversed by EP4 receptor antagonists. 17-pt-PGE2 increased the resistance of pulmonary microvascular endothelial cells and prevented thrombin-induced disruption of endothelial junctions. Again, these effects were not mediated via EP1 or EP3 but through activation of the EP4 receptor, as demonstrated by the lack of effect of more selective EP1 and EP3 receptor agonists, prevention of these effects by EP4 antagonists and EP4 receptor knock-down by siRNA. In contrast, the aggregation enhancing effect of 17-pt-PGE2 in human platelets was mediated via EP3 receptors. Our results demonstrate that 17-pt-PGE2 enhances the endothelial barrier in vitro on pulmonary microvascular endothelial cells, and accordingly ameliorates the recruitment of neutrophils, via EP4 receptors in vivo. This suggests a beneficial effect of 17-pt-PGE2 on pulmonary inflammatory diseases. Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Blood Platelets - drug effects
- Blood Platelets - metabolism
- Dinoprostone - analogs & derivatives
- Dinoprostone - pharmacology
- Disease Models, Animal -
- Endothelial Cells - drug effects
- Endothelial Cells - metabolism
- Gene Knockdown Techniques -
- Humans -
- Inflammation - drug therapy
- Inflammation - pathology
- Lipopolysaccharides - toxicity
- Male -
- Mice -
- Mice, Inbred BALB C -
- Neutrophil Infiltration - drug effects
- Pneumonia - drug therapy
- Pneumonia - pathology
- RNA, Small Interfering - administration & dosage
- Receptors, Prostaglandin E, EP1 Subtype - agonists
- Receptors, Prostaglandin E, EP3 Subtype - agonists
- Receptors, Prostaglandin E, EP4 Subtype - agonists
- Receptors, Prostaglandin E, EP4 Subtype - genetics
- Find related publications in this database (Keywords)
- 17-Phenyl-trinor-prostaglandin E-2
- EP receptors
- Endothelial barrier function
- Vascular hyperpermeability
- Platelet aggregation
- Pulmonary inflammation